粪便检测异常患者结肠镜检查相关不良事件:系统综述与结局荟萃分析
该系统综述与荟萃分析纳入31项研究、共771730例因粪便免疫化学试验(FIT)或愈创木脂粪便隐血试验(gFOBT)阳性而接受结肠镜检查的筛查对象,评估结肠镜相关不良事件。总体严重不良事件合并发生率为0.42%(CI 0.20-0.64),穿孔0.13%、出血0.3%、死亡0.01%,作者认为风险极小。
要点
- 31项研究共771730例结肠镜,总体严重不良事件合并发生率0.42%(CI 0.20-0.64)。
- gFOBT异常者严重不良事件发生率0.2%(CI 0.1-0.3),FIT阳性者为0.4%(CI 0.2-0.7)。
- 穿孔、出血、死亡合并发生率分别为0.13%、0.3%、0.01%。
核心结论
- 在粪便检测异常后进行的结肠镜检查中,严重不良事件、穿孔、出血和死亡的总体风险极小。
研究设计与样本
- 系统综述与荟萃分析,检索于2021年1月进行,由医学图书馆员协助,纳入报告有组织结直肠癌筛查项目中结肠镜相关不良事件的研究。
- 共纳入31项研究,涉及接受gFOBT或FIT结直肠癌筛查的771730例结肠镜检查。
- 采用随机效应模型进行荟萃分析,结果以合并比例及95%置信区间(CI)表示。
主要发现
- 整个患者队列的总体严重不良事件合并发生率为0.42%(CI 0.20-0.64);I²=38.76%。
- gFOBT异常患者中严重不良事件发生率为0.2%(CI 0.1-0.3);I²=24.6%。
- FIT阳性患者中严重不良事件发生率为0.4%(CI 0.2-0.7);I²=48.89%。
- 穿孔、出血和死亡的总体合并发生率分别为0.13%(CI 0.09-0.21;I²=22.84%)、0.3%(CI 0.2-0.4;I²=35.58%)和0.01%(CI 0.00-0.01;I²=33.21%)。
临床怎么用
- 原文未据此给出推荐。
局限性
- 原文未报告局限性。
以上解读依据论文摘要(全文未开放获取或许可不允许翻译转载)。
原文
INTRODUCTION: Colorectal cancer (CRC) screening programs based on the fecal immunochemical test (FIT) and guaiac-based fecal occult blood (gFOBT) are associated with a substantial reduction in CRC incidence and mortality. We conducted a systematic review and comprehensive meta-analysis to evaluate colonoscopy-related adverse events in individuals with a positive FIT or gFOBT. METHODS: A systematic and detailed search was run in January 2021, with the assistance of a medical librarian for studies reporting on colonoscopy-related adverse events as part of organized CRC screening programs. Meta-analysis was performed using the random-effects model, and the results were expressed for pooled proportions along with relevant 95% confidence intervals (CIs). RESULTS: A total of 771,730 colonoscopies were performed in patients undergoing CRC screening using either gFOBT or FIT across 31 studies. The overall pooled incidence of severe adverse events in the entire patient cohort was 0.42% (CI 0.20-0.64); I2 = 38.76%. In patients with abnormal gFOBT, the incidence was 0.2% (CI 0.1-0.3); I2 = 24.6%, and in patients with a positive FIT, it was 0.4% (CI 0.2-0.7); I2 = 48.89%. The overall pooled incidence of perforation, bleeding, and death was 0.13% (CI 0.09-0.21); I2 = 22.84%, 0.3% (CI 0.2-0.4); I2 = 35.58%, and 0.01% (CI 0.00-0.01); I2 = 33.21%, respectively. DISCUSSION: Our analysis shows that in colonoscopies performed after abnormal stool-based testing, the overall risk of severe adverse events, perforation, bleeding, and death is minimal.
引用
- Chandan S, Facciorusso A, Yarra P, et al. Colonoscopy-Related Adverse Events in Patients With Abnormal Stool-Based Tests: A Systematic Review of Literature and Meta-analysis of Outcomes. Am J Gastroenterol. 2022. PMID: 35029161. doi:10.14309/ajg.0000000000001614
供执业医师工作参考,不替代临床判断;数值与分级以指南原文为准。